adobe stock - Yanina Barcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
ADVERTISEMENT